Products
Damoctocog alfa pegol was approved as a preparation for solution for injection in the United States and the EU in 2018 and in many countries in 2019 (Jivi).
Structure and properties
Damoctocog alfa pegol is a pegylated, B-domain-deleted, conjugated, recombinant blood coagulation factor VIII (rFVIII). The molecular mass is approximately 234 kDa. The drug is produced by biotechnological methods.
Effects
Damoctocog alfa pegol (ATC B02BD02) temporarily replaces the missing blood clotting factor VIII, which is insufficient for hemostasis in patients with congenital hemophilia A. Due to pegylation, the half-life and dosing interval are prolonged and the AUC is increased. This compared with natural or recombinant factor VIII.
Indications
For the prevention and treatment of bleeding in pretreated patients (PTPs) ≥12 years of age with hemophilia A (congenital factor VIII deficiency). The drug does not contain von Willebrand factor.
Dosage
According to the SmPC. The drug is injected intravenously.
Contraindications
Full precautions can be found in the drug label.
Adverse effects
The most common possible adverse effects include headache, cough, and fever.
